相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
T. E. Hutson et al.
BRITISH JOURNAL OF CANCER (2014)
Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
Huixin Yu et al.
CLINICAL PHARMACOKINETICS (2014)
Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662
M. H. M. Diekstra et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
B. Beuselinck et al.
BRITISH JOURNAL OF CANCER (2013)
Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
O. Huillard et al.
BRITISH JOURNAL OF CANCER (2013)
Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate
P. Penot et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
Hye Ryun Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer
Masahide Fukudo et al.
CLINICAL PHARMACOKINETICS (2013)
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
Ezzeldin M. Ibrahim et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress
Karen E. Swales et al.
CARDIOVASCULAR RESEARCH (2012)
The Relationship between Drug Clearance and Body Size Systematic Review and Meta-Analysis of the Literature Published from 2000 to 2007
Sarah C. McLeay et al.
CLINICAL PHARMACOKINETICS (2012)
Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics
Tomoyuki Mizuno et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Jennifer J. Griggs et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
Pascaline Boudou-Rouquette et al.
PLOS ONE (2012)
An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity
Carla M. M. Prado et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
Astrid A. M. van der Veldt et al.
CLINICAL CANCER RESEARCH (2011)
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors Focus on Pyrimidines, Pyridines and Pyrroles
Paola Di Gion et al.
CLINICAL PHARMACOKINETICS (2011)
Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1′-Hydroxylation
Minako Sugiyama et al.
DRUG METABOLISM AND DISPOSITION (2011)
The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer: Our Experience and Review of Literature
G. Pasqualetti et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2011)
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Jesus Garcia-Donas et al.
LANCET ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities
Christian Kollmannsberger et al.
ONCOLOGIST (2011)
ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma
T. Mizuno et al.
ANNALS OF ONCOLOGY (2010)
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Alessandro Schipani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma
Benoit Blanchet et al.
CLINICA CHIMICA ACTA (2009)
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
Brett E. Houk et al.
CLINICAL CANCER RESEARCH (2009)
Influence of Lean Body Weight on Anticancer Drug Clearance
R. H. J. Mathijssen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Robert G. Maki et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
Nielka P. van Erp et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression
Pei-Chieng Cha et al.
JOURNAL OF HUMAN GENETICS (2009)
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics
Bin Zhang et al.
PHARMACOGENOMICS (2008)
CYP3A5 and CYP3A4 but not MDR1 single-nucleotide Polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients
D. R. J. Kuypers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values
Andrew S. Levey et al.
CLINICAL CHEMISTRY (2007)
Regulation of vascular tone during pregnancy - A novel role for the pregnane X receptor
Kathryn A. Hagedorn et al.
HYPERTENSION (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Targeted therapy for metastatic renal cell carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
BI Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Quantification of lean bodyweight
S Janmahasatian et al.
CLINICAL PHARMACOKINETICS (2005)
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2
S Mizuarai et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Relationships between body composition parameters and fluorouracil pharmacokinetics
M Gusella et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
分享论文
